NDANASALSPRAY, METERED
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
6/8 — Strong
ZAVZPRET (zavegepant) by Pfizer. Approved for migraine. First approved in 2023.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZAVZPRET (zavegepant) is a nasal spray small molecule approved by the FDA in March 2023 for migraine treatment, with exploratory indications in COVID-19 and asthma. The mechanism of action and pharmacologic class are not publicly detailed in available data. Patients with acute migraine episodes represent the primary target population.
$0.002BPart D
Peak5.4 years to LOEEarly-stage peak product with modest Part D uptake (1,847 claims in 2023); commercial team expansion likely limited pending market penetration acceleration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (10)
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
Started Sep 2025
0Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Started May 2025
16 enrolled
Acute Treatment of Migraine
A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women
Started Jun 2024
12 enrolled
Healthy
A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
Started Nov 2023
1,414 enrolled
Migraine
A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants
Started Oct 2023
13 enrolled
Healthy
Worked on ZAVZPRET at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.